D
Y-mAbs Therapeutics, Inc. YMAB
$5.35 $0.071.33%
Recommendation
Sell
Prev Close
$5.28
Volume
167,489
Avg Vol (90D)
222,860
Market Cap
$230.31M
Dividend & Yield
--
52-Week Range
$2.70 - $15.89
P/E (TTM)
--
EPS (TTM)
-$0.8973
My Lists My Alerts
Report
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of "Hold" from Analysts
9/23/2023 - Zolmax
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)
9/21/2023 - PR Newswire
Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology
9/21/2023 - Globe Newswire
Y-mAbs Therapeutics (YMAB, $5.23) entered Uptrend as Momentum indicator ascends above 0 level on Sep 19, 2023
9/20/2023 - Tickeron - Stocks
Y-mAbs Therapeutics (YMAB, $4.99) Moving Average Convergence Divergence (MACD) Histogram turned positive on September 14, 2023
9/15/2023 - Tickeron - Stocks
AIGH Capital Management LLC Buys New Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
9/10/2023 - Ticker Report
XTX Topco Ltd Buys 124,703 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
9/9/2023 - Zolmax
Y-mAbs to Participate at Upcoming Investor Conferences in September
9/6/2023 - Globe Newswire
Y-mAbs Therapeutics (YMAB, $5.05) Moving Average Convergence Divergence (MACD) Histogram turned negative on August 31, 2023
9/1/2023 - Tickeron - Stocks
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Up 52.4% in August
8/29/2023 - Zolmax
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Sees Significant Increase in Short Interest
8/28/2023 - Ticker Report
Y-mAbs Therapeutics (YMAB, $5.56) Stochastic Oscillator left the overbought zone on August 25, 2023
8/26/2023 - Tickeron - Technical Analysis
Y-mAbs Therapeutics (YMAB, $5.56) entered Uptrend as Momentum indicator ascends above 0 level on Aug 25, 2023
8/26/2023 - Tickeron - Stocks
JPMorgan Chase & Co. Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $7.00
8/26/2023 - Ticker Report
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $7.00 at JPMorgan Chase & Co.
8/25/2023 - Zolmax
Y-mAbs Therapeutics (YMAB, $6.07) Aroon Indicator entered a Downtrend on August 23, 2023.
8/24/2023 - Tickeron - Stocks
Connor Clark & Lunn Investment Management Ltd. Acquires 3,194 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
8/24/2023 - Zolmax
Wall Street Analysts Think Y-mAbs Therapeutics, Inc. (YMAB) Could Surge 88.55%: Read This Before Placing a Bet
8/23/2023 - Zacks Investment Research
Y-mAbs Therapeutics (YMAB, $6.29) Aroon Indicator entered a Downtrend on August 22, 2023.
8/23/2023 - Tickeron - Stocks
Y-mAbs Therapeutics (YMAB, $6.29) Stochastic Oscillator left the overbought zone on August 22, 2023
8/23/2023 - Tickeron - Stocks
Y-mAbs Therapeutics price target lowered to $7 from $8 at JPMorgan
8/22/2023 - The Fly
Y-mAbs Therapeutics (YMAB, $6.13) price may drop as it broke higher Bollinger Band on Aug 21, 2023
8/22/2023 - Tickeron - Technical Analysis
Y-mAbs Therapeutics (YMAB, $6.13) Aroon Indicator entered a Downtrend on August 21, 2023.
8/22/2023 - Tickeron - Technical Analysis
Y-mAbs Therapeutics (YMAB, $5.63) Aroon Indicator entered a Downtrend on August 18, 2023.
8/19/2023 - Tickeron - Technical Analysis
Y-mAbs Therapeutics (YMAB, $5.63) entered Uptrend as Momentum indicator ascends above 0 level on Aug 18, 2023
8/19/2023 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
$84.99M
EBITDA (TTM)
-$25.06M
EBIT (TTM)
-$25.92M
Net Income (TTM)
-$39.06M
Balance Sheet
Total Assets (Q)
$132.40M
Total Debt (Q)
$1.25M
Total Liabilities (Q)
$27.72M
Book Value Per Share (Q)
$2.40
Cash Flow
Cash from Operations (TTM)
-$45.75M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$52.00K
Net Change in Cash (TTM)
-$45.76M
Filings
Filing Date
Thursday, August 10, 2023
Period Date
Friday, June 30, 2023
Next Filing
Week of Nov 6 and 10 (est)
Price History
Loading...
Beta
2.11
7-Day Total Return
7.21%
30-Day Total Return
-4.80%
60-Day Total Return
-21.21%
90-Day Total Return
-43.92%
Year to Date Total Return
11.23%
1-Year Total Return
-63.03%
2-Year Total Return
-81.90%
3-Year Total Return
-86.04%
5-Year Total Return
-78.36%
52-week Low
Mar 24, 2023 - $2.70
52-week High
Oct 26, 2022 - $15.89
Valuation
Market Cap
$230.31M - Micro Cap
Enterprise Value
$143.65M
Price/Sales (TTM)
2.71
Price/Book (Q)
2.20
Dividends and Shares
Shares Outstanding
43.66M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.ymabs.com
Phone Number
646 885 8505
Address
230 Park Avenue
New York, NY 10169
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer... more
NASDAQ 09/26/2023 4:00PM Eastern Quotes delayed
Weiss Ratings